NCT04643886终止2 期
A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events.
研究概览
简要总结
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
详细描述
This is a Phase 2a, multi-center, open-label, multiple dose study in subjects with geographic atrophy (GA) secondary to dry Age-related Macular Degeneration (dry AMD) to investigate the safety, PK/PD, biomarker and early clinical effect of GEM103 repeat IVT injections.
Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in the study. Subjects who participated in the Phase 1 Study (GEM-CL-10301) as well as treatment naïve subjects that did not participate in the GEM-CL-10301 Study and who meet all eligibility criteria will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 50 years old at the time of signed informed consent.
- •Must have one of the following genetic profiles:
- •Genetic Profile A.
- •Genetic Profile B.
- •BCVA in the study eye of 24 to 83 letters using ETDRS Chart Visual Acuity (VA) Scale (approximately equivalent to Snellen VA of 20/25 to 20/320).
- •Confirmed diagnosis of GA in the study eye where total size of all GA lesions in the study eye must be within 0.5 to 15.01- and 7- disc areas.
- •Sufficiently clear ocular media and able to cooperate with ophthalmic visual function testing and anatomic assessment in the study eye.
- •Understands the full nature and purpose of the study and provides informed consent prior to initiation of any study procedure; all subjects with a reproductive potential must agree to use effective contraceptive methods through the end of study (EOS) Visit.
排除标准
- •Presence of the following ocular conditions - in the study eye:
- •Any history of exudative Age-related Macular Degeneration or choroidal neovascularization.
- •Any active ocular disease or condition that could confound the assessment of the macula or be a contraindication to IVT injection.
- •Any intraocular surgery, with the exception of stable intraocular lens replacement surgery more than 3 months prior to consent.
- •Aphakia or complete absence of the posterior capsule.
- •History of laser therapy to the macula or fundus or extensive laser to the retina.
- •Prior corneal transplant.
- •Presence of any of the following ocular conditions - in either eye:
- •History of herpetic infection.
- •Concurrent disease that could require medical or surgical intervention during the study period.
- •Active uveitis and/or vitritis (grade: trace or above).
- •History of idiopathic or autoimmune-associated uveitis.
- •Active blepharitis, conjunctivitis, keratitis, episcleritis, scleritis, or endophthalmitis.
- •Any ophthalmologic condition that reduces the clarity of the media and that, in the opinion of the Investigator, interferes with ophthalmologic examination.
- •In the opinion of the Investigator, the subject has any prior or ongoing medical condition (e.g., ocular other than dry AMD, systemic, psychiatric) or clinically significant screening laboratory value that may present a safety risk, interfere with study compliance or study follow-up, or confound data interpretation throughout the follow-up period.
- •Female subjects must not be pregnant or lactating, nor plan to become pregnant during the study.
- •Current use of medications known to be toxic to the lens, retina, or optic nerve.
- •Use of any investigational new drug or other experimental treatment in the last 6 months, and/or receipt of any prior gene therapy (e.g., AAV) or ocular device implantation (other than PCIOL placement following cataract surgery)
研究组 & 干预措施
Cohort with Genetic Profile A
Experimental
Subjects will have Genetic Profile A.
Intervention: Biological: GEM103.
干预措施: GEM103 (Drug)
Cohort with Genetic Profile B
Experimental
Subjects will have Genetic Profile B.
Intervention: Biological: GEM103
干预措施: GEM103 (Drug)
结局指标
主要结局
Safety of intravitreal (IVT) injections of GEM103, as measured by number of subjects with ocular adverse events.
时间窗: 18 months
次要结局
- To describe the clinical effect of GEM103 IVT injection, as the change from baseline in best corrected visual acuity (BCVA) scores as assessed by ETDRS scale.(6 months)
- To evaluate the total CFH levels in aqueous humor after GEM103 IVT injection, whenever possible.(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson DiseaseNCT05047523Alexion Pharmaceuticals, Inc.40
已完成
1 期
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid TumorsAdvanced/Metastatic Solid TumorsNCT02665416Hoffmann-La Roche94
已完成
1 期
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid TumorsMetastatic or Locally Advanced Solid TumorsNCT05028556Wuhan YZY Biopharma Co., Ltd.50
招募中
1 期
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCMalignant Pleural EffusionsNSCLC Stage IVNCT05543330Wuhan YZY Biopharma Co., Ltd.116
已完成
1 期
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies SubjectsHematological MalignanciesNCT04283097Kangpu Biopharmaceuticals, Ltd.30